TargetBeta
IRAK4
interleukin 1 receptor associated kinase 4 · also NY-REN-64 · Interleukin 1 receptor associated kinase family
5 programs in company-led studies act on IRAK4, from 5 companies: 0 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (4 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| emavusertibrule | Curis | phase 2 | 32 running | – | NCIt |
| HPB-092rule | Hangzhou Polymed Biopharmaceuticals | phase 1 | 11 running | FLT3 | the studies' text |
| IRAK4 Inhibitor AZD2962rule | AstraZeneca | phase 1 | 11 running | – | NCIt |
| SAR447971 | Sanofi | phase 1 | 11 running | – | the company's pipeline |
| ARD-885rule | Artivila (Shenzhen) Innovation Center | phase 1 | 10 running | IRAK1 | the studies' text |
Conditions their studies are in
- Leukemia, Myeloid, Acute, 2 programs
- Arthritis, Rheumatoid, 1 program
- Hematologic Neoplasms, 1 program
- Hidradenitis, 1 program
- Leukemia, Lymphocytic, Chronic, B-Cell, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Jun 2027HPB-092 · Hangzhou Polymed Biopharmaceuticals · phase 1 · NCT07137637
- Jul 2027emavusertib · Curis · phase 2 · NCT03328078
- Apr 17, 2028SAR447971 · Sanofi · phase 1 · NCT07629336
- Oct 20, 2028IRAK4 Inhibitor AZD2962 · AstraZeneca · phase 1 · NCT07064122
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.